Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Elo Mutual Pension Insurance Co

Elo Mutual Pension Insurance Co cut its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 14,233 shares of the life sciences company’s stock after selling 277 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Illumina were worth $1,486,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ILMN. Envestnet Portfolio Solutions Inc. grew its position in Illumina by 426.0% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 15,460 shares of the life sciences company’s stock worth $2,123,000 after buying an additional 12,521 shares during the period. Findlay Park Partners LLP purchased a new position in shares of Illumina in the first quarter valued at $100,120,000. Jupiter Asset Management Ltd. acquired a new position in shares of Illumina during the 1st quarter worth $4,527,000. US Bancorp DE boosted its position in shares of Illumina by 33.9% in the 1st quarter. US Bancorp DE now owns 31,600 shares of the life sciences company’s stock worth $4,339,000 after buying an additional 8,001 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in Illumina by 41.4% in the 1st quarter. BNP Paribas Financial Markets now owns 390,035 shares of the life sciences company’s stock valued at $53,560,000 after acquiring an additional 114,263 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

Illumina stock opened at $131.20 on Friday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04. The firm has a market capitalization of $20.90 billion, a P/E ratio of -16.10 and a beta of 1.15. The firm has a fifty day moving average of $125.25 and a 200-day moving average of $120.67. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $148.19.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.12 by $0.24. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period last year, the company posted $0.32 earnings per share. The firm’s revenue was down 5.4% compared to the same quarter last year. As a group, analysts predict that Illumina, Inc. will post 3.62 EPS for the current year.

Analyst Ratings Changes

ILMN has been the subject of a number of analyst reports. Jefferies Financial Group began coverage on Illumina in a report on Monday, June 3rd. They issued a “hold” rating and a $115.00 price target for the company. Scotiabank cut their price objective on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research report on Thursday, August 15th. Stephens reissued an “overweight” rating and set a $170.00 price objective on shares of Illumina in a research note on Wednesday, July 10th. Evercore ISI lowered their target price on shares of Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a research note on Tuesday, June 11th. Finally, TD Cowen raised Illumina from a “hold” rating to a “buy” rating and increased their price target for the stock from $126.00 to $144.00 in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $151.05.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.